Johnson & Johnson Insider Unloads Stock as Company Sees Strong Quarterly Performance
Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson (J&J), has made significant stock transactions. On August 17, 2026, she exercised employee stock options to acquire 15,000 shares of common stock, with an exercise price of $115.67 per share.
The acquisition cost totaled $1.735 million, and these options were awarded under the company's Long-Term Incentive Plan, becoming exercisable on their third anniversary. Following this, Taubert sold the same number of shares she had acquired, generating approximately $3.95 million from the sale.
The shares were sold at a weighted average price of $263.36 per share, with individual trades ranging from $263.30 to $263.48 per share. The total value received from these sales amounted to $3,950,400.